Original title: New blood cancer drug launched in China
Report from our newspaper (Qiu Yuwen) A few days ago, Roche’s innovative product in the field of blood diseases, Univa (common name: velpertuzumab), was officially commercialized in China, marking a new breakthrough in the treatment of diffuse large B-cell lymphoma in China. treatment options.
Lymphoma is one of the most common blood cancers. Relevant data show that the overall five-year survival rate of lymphoma in China is only 38.4%, which is still far from the target of 46.6% for the overall five-year survival rate of cancer patients in 2030 proposed in the “Healthy China 2030 Planning Outline”. In recent years, innovative therapies and cutting-edge treatment technologies for lymphoma have emerged continuously, providing an opportunity to further improve the diagnosis and treatment of lymphoma and improve the prognosis of patients, bringing more expectations to patients with blood diseases, and giving patients greater access to innovative drugs more urgent needs.
“There are many types of lymphoma, and the treatment needs of patients are becoming more and more diversified.” Gu Hongfei, founder of Lymphoma Home, said, “In recent years, the financial burden of treatment for patients and their families has always been the most concerned issue among the patient group , We hope that the national multi-level medical security system can be further improved, and on the basis of the basic security of medical insurance, more and more innovative payment methods can be expanded to allow more and more patients to have the opportunity to benefit from innovative treatments.”
Since 2020, with the support of innovative policies in the field of domestic drug supervision, Urava, as one of the urgently needed innovative drugs for the clinical treatment of lymphoma, has successively been launched in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, the Guangdong-Hong Kong-Macao Greater Bay Area and Tianjin Autonomous Region. The trade zone adopted the first-in-first-test policy and was included in the drug catalog for clinical use. At the same time, according to the information announced by the government, the regional benefit-type commercial supplementary medical insurance, including Tianjin Huimin Insurance and Hainan Boao Lecheng Global Special Drug Insurance, has included them in the coverage of innovative special drugs.
(Editors in charge: Jiao Long, Zhou Wanting)
Share for more people to see
